Hemostemix Closes CDN$280,594 Private Placement

Executive Summary

• Hemostemix Inc. received conditional TSX Venture Exchange approval for a non‑brokered private placement of 2,244,752 common shares at CDN $0.125 per share, amounting to CDN $280,594.
• Proceeds are earmarked for general working capital, ongoing operational expenses, and business development activities.
• All issued securities are subject to a four‑month hold period under Canadian securities laws.

Key Details

• Offering Size: CDN $280,594 total gross proceeds.
• Shares Issued: 2,244,752 common shares.
• Price per Share: CDN $0.125.
• Conditional Approval: TSX Venture Exchange conditionally approved the placement; final issuance pending final TSXV approval.
• Investor Status: Investor is arm’s‑length and not a related party at time of disclosure (per TSXV Policy 4.1).
• Use of Proceeds: General working capital, support for continuing operational expenses, and business development activities.
• Holding Period: Four‑month hold period from closing date per Canadian securities regulations; additional restrictions may apply in other jurisdictions.
• No Undisclosed Material Changes: Company confirms no material fact or change has been omitted from prior disclosures.

Notable Quotes

(None provided in the release)